Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
Braz. j. infect. dis
;
15(3): 253-261, May-June 2011. tab
Artículo
en Inglés
| LILACS
| ID: lil-589958
ABSTRACT
OBJECTIVES: To describe laboratory abnormalities among HIV-infected women and their infants with standard and increased lopinavir/ritonavir (LPV/r) dosing during the third trimester of pregnancy. METHODS: We evaluated data on pregnant women from NISDI cohorts (2002-2009) enrolled in Brazil, who received at least 28 days of LPV/r during the third pregnancy trimester and gave birth to singleton infants. RESULTS: 164 women received LPV/r standard dosing [(798/198 or 800/200 mg/day) (Group 1)] and 70 increased dosing [(> 800/200 mg/day) (Group 2)]. Group 1 was more likely to have advanced clinical disease and to use ARVs for treatment, and less likely to have CD4 counts > 500 cells/mm³. Mean plasma viral load was higher in Group 2. There were statistically significant, but not clinically meaningful, differences between groups in mean AST, ALT, cholesterol, and triglycerides. The proportion of women with Grade 3 or 4 adverse events was very low, with no statistically significant differences between groups in severe adverse events related to ALT, AST, total bilirubin, cholesterol, or triglycerides. There were statistically significant, but not clinically meaningful, differences between infant groups in ALT and creatinine. The proportion of infants with Grade 3 or 4 adverse events was very low, and there were no statistically significant differences in severe adverse events related to ALT, AST, BUN, or creatinine. CONCLUSION: The proportions of women and infants with severe laboratory adverse events were very low. Increased LPV/r dosing during the third trimester of pregnancy appears to be safe for HIV-infected women and their infants.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Complicaciones Infecciosas del Embarazo
/
Pirimidinonas
/
Infecciones por VIH
/
Inhibidores de la Proteasa del VIH
/
Ritonavir
/
Fármacos Anti-VIH
Tipo de estudio:
Estudio de etiología
/
Estudio de incidencia
/
Estudio observacional
/
Factores de riesgo
Límite:
Femenino
/
Humanos
/
Masculino
/
Recién Nacido
/
Embarazo
País/Región como asunto:
America del Sur
/
Brasil
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2011
Tipo del documento:
Artículo
/
Documento de proyecto
País de afiliación:
Argentina
/
Brasil
/
Estados Unidos
Institución/País de afiliación:
Hospital Femina/BR
/
Hospital de Agudos Dra. Cecilia Grierson/AR
/
Hospital dos Servidores do Estado/BR
/
Irmandade da Santa Casa de Misericórdia de Porto Alegre/BR
/
NIH/US
/
Universidade Federal de Minas Gerais/BR
/
Universidade de Caxias do Sul/BR
/
Universidade de São Paulo/BR
/
Westat/US
Similares
MEDLINE
...
LILACS
LIS